BN · rank #14 · 2026-07-27
ACLS
NASDAQ · $4.12B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of the factors below; drives the rank. | 0.12 |
|---|---|
| Forward revenue growth Consensus forward revenue growth. | +9.6% |
| Forward net margin Consensus forward net margin. | +13.8% |
| Net margin TTM Trailing twelve month net margin. | +11.9% |
| Margin expansion Forward minus trailing net margin (percentage points). | +1.8% |
| Forward PEG Forward P/E to growth. Below 1 is cheap for the growth. | 1.45 |
| Debt / FCF Net debt relative to free cash flow. Lower is safer. | 0.47× |
| Analyst upside Spread between the consensus 12m target and the current price. | +26.5% |
| Last EPS surprise Most recent reported EPS versus consensus. | +1% |
| Market cap (USD) | $4.12B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
ACLS makes ion implantation systems and services for semiconductor fabs, serving a niche process bottleneck in memory and mature-node manufacturing.
Rationale
The signal fits a bottleneck-solver setup because Axcelis has recurring CS&I revenue, strong core share in implant tools, and exposure to a memory-led second-half recovery that supports mid-teens margins and modest growth.
Material risks
- 1The thesis breaks if larger OEMs or alternate process flows commoditize ion implantation and erode Axcelis’ differentiated position and pricing power.
- 2Memory and mature-node capex is cyclical, so a delayed DRAM/HBM recovery or China/export-control disruption could push orders and backlog lower.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.